ArticleJournal of cellular and molecular medicine2008
Down-regulation of osteopontin attenuates breast tumour progression in vivo.
Article in Journal of cellular and molecular medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 43 citations in OpenAlex.
- Article
- New Insights into LINC00346 and its Role in Disease.Frontiers in cell and developmental biology · 2021Review
- Article
- Osteopontin at the Crossroads of Inflammation and Tumor Progression.Mediators of inflammation · 2017Review
- Osteopontin regulates proliferation, apoptosis, and migration of murine claudin-low mammary tumor cells.BMC cancer · 2016Article
- Functional characterization of stromal osteopontin in melanoma progression and metastasis.PloS one · 2013Article
- Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer.Journal of experimental & clinical cancer research : CR · 2012Article
- Article
- Pre- and post-translational regulation of osteopontin in cancer.Journal of cell communication and signaling · 2011Article
- Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma.Immunology · 2011Article
- Aerosol delivery of small hairpin osteopontin blocks pulmonary metastasis of breast cancer in mice.PloS one · 2010Article
- Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells.Radiation oncology (London, England) · 2010Article
- A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo.Cancer immunology, immunotherapy : CII · 2010Article
- Osteopontin: an effector and an effect of tumor metastasis.Current molecular medicine · 2010Review
- Osteopontin regulates human glioma cell invasiveness and tumor growth in mice.Neuro-oncology · 2010Article
- Adenosine and osteopontin contribute to the development of chronic obstructive pulmonary disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2010Article
- Osteopontin and oral carcinogenesis.Journal of cellular and molecular medicine · 2008Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Development of breast tumour malignancies results in enhanced expression of various oncogenic molecules. Elevated expression of osteopontin (OPN) in higher grades of breast carcinoma correlates with enhanced expressions of several oncogenic molecules (urokinase-type plasminogen activator [uPA], matrix metalloproteinase-2/-9 [MMP-2 and -9]) and increased angiogenic potential of breast carcinoma. In this study, using in vitro and multiple in vivo models, we have demonstrated that silencing of OPN by its specific small interfering RNA (siRNA) down-regulates the expressions of oncogenic molecules such as uPA, MMP-2 and -9 resulting in inhibition of in vitro cell motility and in vivo tumourigenicity in mice. Moreover our results demonstrated that OPN-/- mice showed slower progression of tumour growth in breast cancer model as compared to wild-type mice. Furthermore, the data showed that injection of carcinogenic compound, pristane (2, 6,10,14-tetramethylpen-tadecane) induces breast tumour progression leading to enhanced expression of OPN and other oncogenic molecules in mammary fat pad of nude- and wild-type mice but not in OPN-/- mice. However, intratumoural injection of OPN siRNA to pristane-induced tumour significantly suppressed these effects. Our data revealed that knocking down of OPN effectively curb breast cancer progression and further suggested that developing of OPN-based therapeutics might be an emerging approach for the next generation of breast cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.